enGene (NASDAQ:ENGN) Now Covered by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of enGene (NASDAQ:ENGN) in a research note published on Tuesday morning, Marketbeat reports. The firm issued an overweight rating and a $26.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on ENGN. UBS Group cut shares of enGene from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. JMP Securities reiterated a “market outperform” rating and set a $18.00 target price on shares of enGene in a research report on Monday, December 23rd. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. HC Wainwright started coverage on shares of enGene in a research report on Monday, December 23rd. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Raymond James started coverage on shares of enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.89.

enGene Trading Down 6.8 %

Shares of enGene stock opened at $6.15 on Tuesday. The stock has a market capitalization of $271.71 million, a P/E ratio of -10.59 and a beta of -0.65. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The company has a 50-day simple moving average of $6.77 and a 200 day simple moving average of $7.21. enGene has a 12-month low of $4.42 and a 12-month high of $18.40.

enGene (NASDAQ:ENGN) last announced its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Research analysts expect that enGene will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of enGene

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Fcpm Iii Services B.V. raised its holdings in shares of enGene by 11.0% in the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock valued at $64,057,000 after purchasing an additional 954,610 shares during the last quarter. VR Adviser LLC increased its holdings in enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after buying an additional 1,480,573 shares during the last quarter. Deep Track Capital LP increased its holdings in enGene by 74.8% during the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock worth $30,308,000 after buying an additional 1,949,942 shares during the last quarter. Blue Owl Capital Holdings LP increased its holdings in enGene by 3.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after buying an additional 101,006 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in enGene by 84.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock worth $8,145,000 after buying an additional 561,797 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.